(Tiper Stock Exchange) – Intesa Sanpaolo has lowered to 46.1 euros per share (from 51.1 euros) the target price on BB Biotechinvestment company in the field of biotechnology and listed on Euronext STAR Milan, confirming the judgment on the title to “hold“.
Analysts observe that in an M&A market still influenced by an unfavorable macroeconomic context, BB Biotech’s attention in the second half of 2023 will be clinical trial results and drug approvals for portfolio holdings.
Furthermore, they recall that the management communicated that they had asked for the delisting from the Milan Stock Exchange due to very low trading volumes and the exclusion from the FTSE Italia STAR index. The stock will continue to be listed in Germany and Switzerland.